https://www.fda.gov/news-events/press-announcements/fda-approves-first-topical-gene-therapy-treatment-wounds-patients-dystrophic-epidermolysis-bullosa
0
0
FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa - FDA.gov
5/19/23 at 5:00pm
Organization
FDA.gov
Author
Office of the Commissioner
Details
45 words
Summarize
Health Conditions Business & Industrial Vyjuvek FDA First Topical Gene Therapy for Treatment of Wounds Dystrophic Epidermolysis Bullosa FDA.gov mutation(s)
FDA approves Vyjuvek, a gene therapy for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in
Create an account or login to join the discussion